Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

Zotero / K4D COVID-19 Health Evidence Summaries Group / Top-Level Items 2021-08-25

Type Journal Article Author Jerald Sadoff Author Mathieu Le Gars Author Georgi Shukarev Author Dirk Heerwegh Author Carla Truyers Author Anne M. de Groot Author Jeroen Stoop Author Sarah Tete Author Wim Van Damme Author Isabel Leroux-Roels Author Pieter-Jan Berghmans Author Murray Kimmel Author Pierre Van Damme Author Jan de Hoon Author William Smith Author Kathryn E. Stephenson Author Stephen C. De Rosa Author Kristen W. Cohen Author M. Juliana McElrath Author Emmanuel Cormier Author Gert Scheper Author Dan H. Barouch Author Jenny Hendriks Author Frank Struyf Author Macaya Douoguih Author Johan Van Hoof Author Hanneke Schuitemaker URL https://www.nejm.org/doi/10.1056/NEJMoa2034201 Rights Copyright © 2021 Massachusetts Medical Society. All rights reserved. Volume 384 Pages 1824-1835 Publication New England Journal of Medicine Date 13/01/2021 Loc. in Archive world Extra Publisher: Massachusetts Medical Society DOI 10.1056/NEJMoa2034201 Library Catalog www.nejm.org Language en Abstract Original Article from The New England Journal of Medicine — Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine